Estimating a Treatment Effect by the Accelerated Hazards Model
In randomized clinical trials, when the outcome of interest is time-to-event, Cox’s proportional hazards model is often used to identify the treatment effect. This model usually assumes that the treatment effect is a constant of proportionality between the hazard function of the treatment and control arms. This assumption, however, is not applicable in certain trials. A simple alternative called the accelerated hazards model is then introduced when the treatment is believed to accelerate or decelerate the underlying risk progression over time. The treatment effect is therefore characterized by the hazard progression time ratio. Survival data from a randomized placebo-controlled trial (Brem, et al., 1995), which evaluates the effectiveness of biodegradable polymers with carmustine to treat malignant gliomas, is used to illustrate the model.
Clinical Trials | Statistical Models | Survival Analysis
Chen, Ying Qing and Wang, Mei-Cheng, "Estimating a Treatment Effect by the Accelerated Hazards Model" (October 1999). U.C. Berkeley Division of Biostatistics Working Paper Series. Working Paper 79.